Overview

Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

Status:
Active, not recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences